diaDexus, Inc. announced the appointment of Pat Arensdorf as general manager and head of the heart failure business unit with responsibility for the development and commercialization of the company's heart failure biomarkers. Most recently, he was chief executive officer of Critical Diagnostics, where he led a new regulatory strategy resulting in the most recent FDA clearance of a novel heart failure biomarker.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- USD | -.--% | -.--% | -.--% |
2021 | Diadexus, Inc. Went Out of Business | CI |
2018 | Motion for Asset Sale Approved for Diadexus, Inc. | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 410 | |
-28.82% | 1.34B | |
-17.49% | 57.9M |
- Stock Market
- Equities
- DDXSQ Stock
- News Diadexus, Inc.
- DiaDexus, Inc. Appoints Pat Arensdorf as General Manager and Head of the Heart Failure Business Unit